

## **Veterinary Drug Submission Fee Application Form**

This form must be completed for every submission. In addition, please complete and submit only the section(s) which are necessary. One form may be used for multiple strengths of a single dosage form. However, individual Drug Submission Application Forms are still required to be submitted for each formulation strength.

- For a New Drug Submission complete Section 1.
- For a Supplement to a New Drug Submission complete Section 2.
- For an Abbreviated New Drug Submission or Supplement to an Abbreviated New Drug Submission complete Section 3.
- For a DIN Application complete Section 4.
- For a Preclinical (Investigational) New Drug Submission complete Section 5.
- For a Notifiable Change or Protocol Review complete Section 6.
- For an Experimental Studies Certificate Application complete an ESC Fee Application Form.
- For an Emergency Drug Release complete an EDR Application and Fee Form

yes no	a phased submission review	? If this is an app \$1,000.	plication for a fee reduction, please remit
Where the submission	on fee total is <\$10,000, th	e full fee is due on filing.	
Where the submission	on fee total is >\$10,000, 10	% of the total fee is due	on filing.
lentification			
Product name			
Name of Manufacturer/Spo	nsor as per Drug Submission Ap	pplication	
Address of Manufacturer/S	oonsor		
, taar ooo or manarada oo oo	, sancon		
Contact Person	Т	elephone	Fax
Billing address (if different)		Billing Contact P	Person
Submission Information			
Dosage Form	!	Route(s) of Administration	
Strength(s) - A product with	multiple strengths (eg. tablet) m	ay be indicated	
and completed form an	nd remittance, made payable		
Receiver General for Ca	-		
Receiver General for Ca Submission and	Knowledge Managemer	nt Division	
Receiver General for Ca Submission and Veterinary Drugs Holland Cross C	Knowledge Managemer S Directorate omplex	nt Division	HPFB use only
Receiver General for Ca Submission and Veterinary Drugs Holland Cross C Ground Floor, S	Knowledge Managemer s Directorate omplex uite 14		HPFB use only
Receiver General for Ca Submission and Veterinary Drugs Holland Cross C Ground Floor, S 11 Holland Aven	Knowledge Managemer s Directorate complex uite 14 ue, Address Locator : 30		HPFB use only
Receiver General for Ca Submission and Veterinary Drugs Holland Cross C Ground Floor, S	Knowledge Managemer s Directorate complex uite 14 ue, Address Locator : 30 A 0K9		HPFB use only
Receiver General for Ca Submission and Veterinary Drugs Holland Cross C Ground Floor, S 11 Holland Aven	Knowledge Managemer s Directorate complex uite 14 ue, Address Locator : 30 A 0K9 HPFB use only		HPFB use only
Receiver General for Ca Submission and Veterinary Drugs Holland Cross C Ground Floor, S 11 Holland Aven Ottawa, ON K1A	Knowledge Managemer s Directorate complex uite 14 ue, Address Locator : 30 A 0K9 HPFB use only	000A	HPFB use only
Receiver General for Ca Submission and Veterinary Drugs Holland Cross C Ground Floor, S 11 Holland Aven Ottawa, ON K1A	Knowledge Managemer s Directorate complex uite 14 ue, Address Locator : 30 A 0K9 HPFB use only	000A	HPFB use only
Receiver General for Ca Submission and Veterinary Drugs Holland Cross C Ground Floor, S 11 Holland Aven Ottawa, ON K1A	Knowledge Managemer s Directorate complex uite 14 ue, Address Locator : 30 A 0K9 HPFB use only	000A	HPFB use only

HC/SC 4360E (Revised December 2005)

Prod	uct Name:	Submission No.:			_ File No.:		
Secti	on 1: New Drug Submiss	ion				HC PR	OTECTED
	(	Component	Fee	x no.	Enter fee here	HPFB (	Jse Only
1.		ended species) for one route, dosage cies. For antiparasitic, several indications	\$15,980				
2.	Efficacy & safety data (int form for an antiparasitic in	ended species) for one route & dosage 1 non-food species.	9,680				
3.		ended species) for one route, dosage cies; or one route, dosage form & 2	23,240				
4.	Efficacy & safety data (int production enhancement	ended species) for a growth promotion or indication in 1 species.	31,470				
5.		ynamic, clinical or bioavailability) data for on to route referred to in item 1, 2 or 3.	2,900				
6.	each additional strength.	ynamic, clinical or bioavailability) data for (1 study to support strengths may be er items 1, 2 or 3, without payment of this	480				
7.	to establish an ADI with a	metabolism & residue depletion studies SF of 1,000, a MRL & a withdrawal m, dosage & route in 1 species.	21,790				
8.	to establish an ADI with a	metabolism & residue depletion studies SF of <1,000, a MRL & a withdrawal m, dosage & route in 1 species.	29,050				
9.		depletion studies to establish a dditional dosage form, dosage or route.	2,900				
10.	established), metabolism	a ADI and a SF of ≤ 1,000 has been & residue depletion studies to establish a d for one dosage form, dosage and route					
11.	ingredient. (A medicinal ir	g for non-compendial medicinal gredient previously evaluated within the rence is made is not required to be re-	4,840				
12.	Chemistry & manufacturin	g for one strength of 1 dosage form	4,840				
13.	Chemistry & manufacturin form submitted with item	g for an additional strength of 1 dosage 12.	2,420				
14.	Change in manufacturer of does not include any of the	of a drug. (Applies only where a NDS e above components.)	250				
	HF	FB use only					
Fee	assessment verified by (pr		Total Fe	ee ►			
Sigr	 nature	 Date					

Prod	uct Name: Submission No.:			File No.:	
Secti	on 2: Supplement to a New Drug Submission				HC PROTECTED
	Component	Fee	x no.	Enter fee here	HPFB Use Only
1.	Efficacy data for an additional indication in 1 species.	\$12,590			
2.	Efficacy & safety data (intended species) for one route & dosage form for an antiparasitic in 1 non-food species.	9,680			
3.	Efficacy & safety data (intended species) for an indication in another species.	15,980			
4.	Efficacy & safety data (intended species) for one route, dosage form & indication in 2 species; or one route, dosage form & 2 indications in 1 species.	23,240			
5.	Efficacy & safety data (intended species) for a growth promotion or production enhancement indication in 1 species.	31,470			
6.	Efficacy & safety data (intended species) for the concurrent use of 2 drugs approved for the same species.	7,740			
7.	Comparative (pharmacodynamic, clinical or bioavailability) data for an additional route. (In addition to route referred to in item 2 or 4.)	2,900			
8.	Comparative (pharmacodynamic, clinical or bioavailability) data for each additional strength. (1 study to support strengths may be included with a SNDS, under item 1, 2 or 3 without payment of this fee.)	480			
9.	For food animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of an approved dosage form in 1 species.	2,900			
10.	For food animals, metabolism & residue depletion studies to establish a MRL & a withdrawal period for one dosage & route of an approved dosage form in an additional species.	14,520			
11.	For food animals, toxicity studies for a change of an established ADI, MRL & withdrawal period.	7,260			
12.	For concurrent use of 2 drugs in a food species, residue depletion studies to determine if extension to withdrawal periods is required.	5,810			
13.	Chemistry & manufacturing for change in source of medicinal ingredient or its manufacturing process.	4,840			
14.	Chemistry & manufacturing for change in formulation or dosage form.	2,420			
15.	Chemistry & manufacturing for change in packaging or sterilization.	1,930			
16.	Chemistry & manufacturing for extension of expiry date.	1,450			
17.	Chemistry & manufacturing for concurrent use of 2 drugs.	1,450			
18.	Chemistry & manufacturing for change in manufacturing site (parenteral or sterile).	480			
19.	Change in manufacturer or brand name of a drug. (Applies only where a SNDS does not include any of the above components.)	250			
	HPFB use only assessment verified by (print):	Total F	ee ▶		
Sigi	nature Date				

Product Name:	<b>Submission No.:</b>	File No.:	

HC PROTECTED

## Section 3: Abbreviated New Drug Submission or Supplement to an Abbreviated New Drug Submission

	Component	Fee	x no.	Enter fee here	НРГВ	Use Only
1.	Any applicable component listed in Section 2.	See Section 2				
2.	Comparative (pharmacodynamic, clinical or bioavailability) data for one route & dosage form.	\$2,900				
3.	For food animals, residue depletion studies to confirm that the withdrawal period(s) for each species falls within the conditions of use for the Canadian reference product.	2,900				
4.	Chemistry & manufacturing for non-compendial medicinal ingredient. (A medicinal ingredient previously evaluated within the last 3 years, to which reference is made is not required to be re-evaluated.)	4,840				
5.	Chemistry & manufacturing for 1 dosage form.	4,840				
6.	Change in manufacturer or brand name of a drug. (Applies only where an abbreviated submission does not include any of the above components.)	250				
	HPFB use only e assessment verified by (print): nature Date	Total Fe	ee ►			

Product Name:	Submission No.:	File No.:	
Section 4: DIN Application			HC PROTECTED

	Component	Fee	x no.	Enter fee here	HPFB On	
1.	Information (other than item 2 below) for DIN application, including the submission of labelling for a second review, if required.	\$720				
2.	Published references or other data.	500				
3.	Change in manufacturer or brand name of a drug. (Applies only where a DIN application does not include any of the above components.)	250				
	HPFB use only  assessment verified by (print):  nature Date	Total Fe	ee ►			

Product Name: Subm	nission No.:	File No.:
--------------------	--------------	-----------

## Section 5: Preclinical (Investigational) New Drug Submission

HC PROTECTED

	Component	Fee	x no.	Enter fee here	HPFB Use Only
1.	Efficacy & safety data (intended species) & protocol for the conduct of clinical studies for one dosage form, route & indication in 1 species.	\$4,840			
2.	Efficacy data & protocol for the conduct of clinical studies for one route & indication with a dosage form for which a NOC has been issued for use in that species.	3,870			
3.	For food animals, toxicity, metabolism & residue depletion studies to establish a temporary ADI, MRL & a withdrawal period for one dosage form, dosage & route in 1 species.	14,520			
4.	For food animals, toxicity, metabolism & residue depletion studies to establish an ADI with a SF of 1,000, a MRL & a withdrawal period for one dosage form, dosage & route in 1 species.	21,790			
5.	For food animals, toxicity, metabolism & residue depletion studies to establish an ADI with a SF of <1,000, a MRL & a withdrawal period for one dosage form, dosage & route in 1 species.	29,050			
6.	For food animals (once a ADI and a SF of ≤1,000 has been established), metabolism studies to establish a withdrawal period for one dosage form, dosage & route in an additional species.	7,260			
7.	Chemistry & manufacturing for 1 dosage form with a non- compendial medicinal ingredient. (A medicinal ingredient previously evaluated within the last 3 years, to which reference is made is not required to be re-evaluated. In that case, the fee for item 8 would apply.)	4,840			
8.	Chemistry & manufacturing for 1 dosage form with a compendial medicinal ingredient.	2,420			
	HPFB use only  assessment verified by (print):	Total Fe	ee ►		
Sign	nature Date				

Product Name:	Submission No.:	File No.:	
	-	_	

## Section 6: Notifiable Change or Protocol Review

**HC PROTECTED** 

Component		x no.	Enter fee here	HPFB Use Only	
Information & material to support an application for a Notifiable change.	\$1,300				
Request for review of scientific information outside of a regular drug submission (i.e. review of a proposed trial protocol).	1,300				
HPFB use only  Fee assessment verified by (print):	Total Fe	ee ►			
Signature Date					